

中国药学会系列期刊/《CAJ-CD》规范执行优秀期刊/美国《化学文摘》荷兰SCOPUS等国际著名检索系统收录  
中国中文核心期刊 中国科技核心期刊 中国科学引文数据库来源期刊



CHINESE JOURNAL OF NEW DRUGS

ISSN 1003-3734  
CN 11-2850/R  
CODEN ZXZHA6

# 中国新药杂志



4  
2018  
Vol.27 | No.4

丙型肝炎病毒抑制剂达拉他韦中国专利申请情况解析  
PD-1/PD-L1抗体临床药理学研究的考虑  
硫酸沙丁胺醇吸入气雾剂递送剂量测定方法比较  
SGLT2抑制剂代谢调控作用的相关研究进展  
青蒿素固体脂质纳米粒经肺给药在大鼠体内的分布

www.newdrug.cn

ISSN 1003-3734



国家食品药品监督管理总局主管



# 目次

半月刊 1992年创刊  
第27卷第4期 2018年2月28日出版

## •新药述评与论坛•

- 369 日本药品上市许可持有人制度下的临床试验保险设置研究对中国的启示.....邹宜誼, 陈云, 柳鹏程, 等  
373 仿制药质量和疗效一致性评价参比制剂备案平台数据分析.....许鸣镛, 关皓月, 崔猛, 等  
379 中国中药领域专利情报分析.....冯雪飞, 袁红梅  
385 丙型肝炎病毒抑制剂达拉他韦中国专利申请情况解析.....蒋君好, 邓萍

## •新药注册与审评技术•

- 390 PD-1/PD-L1抗体临床药理学研究的考虑.....李娜, 王玉珠, 杨进波

## •重大新药创制专项巡礼•

- 398 远志治疗阿尔茨海默病的网络药理学作用机制.....贾皓, 庞晓丛, 赵赢, 等  
405 硫酸沙丁胺醇吸入气雾剂递送剂量测定方法比较.....魏宁漪, 周颖, 陈翠翠, 等

## •综述•

- 409 以患者为中心的个体化制剂新技术研究进展.....初晓阳, 高春红, 葛成, 等  
417 SGLT2抑制剂代谢调控作用的相关研究进展.....温小花, 鞠霖杰, 王春俊, 等  
422 石仙桃属植物非类化学成分研究进展.....胡军, 郭洁, 晏和贵, 等  
429 数学模型在QbD理念实施中的应用及推广.....蒋建兰, 宣建邦, 张凯旋, 等

## •临床研究•

- 437 UPLC-MS/MS法测定人血浆中非那雄胺浓度及2种片剂的生物等效性研究.....王鸿芃, 王曼, 罗柱, 等  
443 匹维溴铵联合复方嗜酸乳杆菌治疗不同亚型肠易激综合症的疗效.....刘晓, 刘亚巍, 蒋楹, 等

## •实验研究•

- 446 天葵子对D-半乳糖致衰老小鼠学习记忆能力的影响.....冯沼润, 何先元, 黄英如  
454 青蒿素固体脂质纳米粒经肺给药在大鼠体内的分布.....王丽, 傅川, 曾明辉, 等  
459 紫杉醇的pH敏感聚合物胶束的制备及其体外释放研究.....王子琪, 王狄狮, 李馨儒, 等  
465 超临界CO<sub>2</sub>流体技术制备布洛芬包合物.....佟童, 裴英, 单冬媛, 等  
471 硫酸氢氯吡格雷片体外溶出曲线相似性评价.....程莹莹, 陈振阳, 曾环想, 等  
477 匹莫范色林片的制备及其体外溶出度评价.....王琳, 杨启家, 陶振明, 等  
483 梯度洗脱HPLC测定奥达特罗的有关物质.....王木兰, 唐克慧, 张春然, 等

[期刊基本参数] CN11-2850/R\*1992\*sm\*A4\*120\*zh\*P\*¥30.00\*\*20\*2018-02

责任编辑 赵文锐 英文审校 魏尔清 杜小莉 张鲸惊

- 369 The enlightenment of Japan's drug clinical trial insurance system under the marketing authorization holder system to China  
ZOU Yi-xuan, CHEN Yun, LIU Peng-cheng, *et al*
- 373 Data analysis of the reference medical product record platform for generic drugs consistency evaluation  
XU Ming-di, GUAN Hao-yue, CUI Meng, *et al*
- 379 Patent information analysis of traditional Chinese medicine in China  
FENG Xue-fei, YUAN Hong-mei
- 385 Analysis of patent applications of the HCV inhibitor daclatasvir in China  
JIANG Jun-hao, DENG Ping
- 390 Consideration on clinical pharmacological studies of anti-PD-1 and anti-PD-L1 antibodies  
LI Na, WANG Yu-zhu, YANG Jin-bo
- 398 Network pharmacology mechanism study on the effective constituents of *Polygala Tenuifolia* for anti-Alzheimer's disease  
JIA Hao, PANG Xiao-cong, ZHAO Ying, *et al*
- 405 Comparison of measurement methods of delivered-dose uniformity of salbutamol sulfate inhalation aerosol  
WEI Ning-yi, ZHOU Ying, CHEN Cui-cui, *et al*
- 409 Progress in researches of patient-centric individualized formulation approaches  
CHU Xiao-yang, GAO Chun-hong, GE Cheng, *et al*
- 417 Recent progress of SGLT2 inhibitors in metabolic regulation  
WEN Xiao-hua, JU Lin-jie, WANG Chun-jun, *et al*
- 422 Review on chemical constituents of phenanthrenes from plants of *Pholidota* genus  
HU Jun, GUO Jie, YAN He-gui, *et al*
- 429 The application and generalization of mathematical models in QbD  
JIANG Jian-lan, XUAN Jian-bang, ZHANG Kai-xuan, *et al*
- 437 Determination of plasma concentration by UPLC-MS/MS and bioequivalence of two finasteride preparations in human  
WANG Hong-qian, WANG Man, LUO Zhu, *et al*
- 443 Efficacy and safety of pinaverium bromide combined with compound eosinophil-lactobacillus in the treatment of irritable bowel syndrome of different subtypes  
LIU Xiao, LIU Ya-wei, JIANG Ying, *et al*
- 446 Effects of *Semiaquilegia adoxoides* on learning and memory of D-galactose-induced aging mice  
FENG Zhao-run, HE Xian-yuan, HUANG Ying-ru
- 454 The distribution of artemisinin solid lipid nanoparticles in rats after pulmonary administration  
WANG Li, FU Chuan, ZENG Ming-hui, *et al*
- 459 Preparation and *in vitro* release evaluation of paclitaxel-loaded pH-sensitive polymeric micelle  
WANG Zi-qi, WANG Di-shi, LI Xin-ru, *et al*
- 465 Preparation of ibuprofen inclusion complex using supercritical CO<sub>2</sub> fluid technology  
TONG Tong, PEI Ying, SHAN Dong-yuan, *et al*
- 471 Evaluation of dissolution curves of clopidogrel hydrogen sulphate tablets *in vitro*  
CHENG Ying-ying, CHEN Zhen-yang, ZENG Huan-xiang, *et al*
- 477 Preparation and *in vitro* dissolution evaluation of pimavanserin tablets  
WANG Lin, YANG Qi-jia, TAO Zhen-ming, *et al*
- 483 Detection of related substances of olodaterol by HPLC with gradient elution  
WANG Shu-lan, TANG Ke-hui, ZHANG Chun-ran, *et al*

**Directed by:** China Food and Drug Administration  
**Sponsored by:** China Medical Science Press  
China National Pharmaceutical Group Corp.  
Chinese Pharmaceutical Association  
**Editor-in-Chief:** SANG Guo-wei  
**Board Chairman:** SHI Sheng-yi  
**Edited by:** Editorial Board of Chinese Journal of New Drugs  
**Published by:** Chinese Journal of New Drugs Co., Ltd.  
**Address:** Room 317, No.3 Chengming Building, No.2 Xizhimen South Street, Xicheng District, Beijing 100035, China  
**Tel:** (010)52722697 / 52722651 / 52723707

**Website:** <http://www.newdrug.cn>  
**E-mail:** [bianjibu@newdrug.cn](mailto:bianjibu@newdrug.cn)  
**Printer:** Beijing Kexin Printing Co., Ltd.  
**Domestic Distribution:** Beijing Post Offices  
**Overseas Distribution:** China International Book Trading Corp.  
(P.O.Box 399 Beijing, China)  
**Domestic Subscription:** Local Post Offices  
**Periodical Registration:** ISSN 1003-3734 CN 11-2850/R  
**Publication Date:** February 28, 2018  
**Copyright:** 2018 by Chinese Journal of New Drugs Co., Ltd.



晴众®

富马酸替诺福韦二吡呋酯片

Tenofovir Disoproxil Fumarate Tablets

广告

# 臻睛真意 惠艾万众

慢性乙型肝炎抗病毒治疗一线药物  
国内率先通过《仿制药质量和疗效一致性评价》  
开展与原研替诺福韦酯五年期“头对头”临床试验



## 晴众®简要处方资料

- 【药品名称】** 商品名：晴众®  
通用名：富马酸替诺福韦二吡呋酯片
- 【适应症】** 本品适用于治疗慢性乙型肝炎成人和≥12岁的儿童患者；与其他抗逆转录病毒药物联用，治疗成人HIV-1感染。
- 【规格】** 300mg
- 【用法用量】** 成人和12岁及以上儿童患者（35kg或以上）口服本品，每日1次，每次300mg，可空腹或与食物同服。
- 【不良反应】** 临床试验中最常见的不良反应包括消化道事件、头痛、头晕、乏力、鼻咽炎、疼痛、皮疹、抑郁、失眠、淀粉酶增加、肝酶升高和肌酐升高等。
- 【禁忌】** 富马酸替诺福韦二吡呋酯片禁用于先前对本药物中任何一种成份过敏的患者。

苏药广审（文）：第2017120671号



（详细资料备索）

@ HTTP://WWW.CTTQ.COM

健康咨询热线：800 828 5598

本广告仅供医学、药学专业人士阅读

万方数据

国内定价：30.00元 国内统一刊号CN11-2850/R 邮发代号82-488 国外代号M4240

正大天晴药业集团  
CHIA TAI TIANGING PHARMACEUTICAL GROUP